Navigation Links
EffRx Announces Issuance of US Patent Providing Further Protection to EX101, Effervescent Alendronate Weekly Dosing Form
Date:7/11/2011

LAUSANNE, Switzerland, July 11, 2011 /PRNewswire/ --


EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company, announces that US patent 7,964,212 was issued on June 21, 2011, enhancing the protection of EX101.

This patent grants significant additional Intellectual Property concerning the EffRx Lead Program, EX101 (70 mg effervescent alendronate for the treatment of osteoporosis).

The extended range of intellectual property in this patent protects effervescent formulations of all the orally administered bisphosphonate osteoporosis medications including risedronate and ibandronate, when delivered in the highly buffered EX101 formulation. The formulation is unique in that it delivers the bisphosphonate to the stomach in a proprietary buffered solution which prevents exposure of the stomach or esophagus to strongly acidified bisphosphonate forms, which are believed to be damaging forms of this drug class.  

Additional claims related to the buffering composition and method of manufacturing were also granted.

An NDA for EX101 has been filed by the FDA. Nycomed has licensed EX101 for territories outside the United States, Canada and Japan, and the product is in registration in many countries.

"There are more and more reports around the world that generic alendronate products have even more GI-side effect problems and thereby less patient compliance than branded bisphosphonate products. We strongly believe that EX101 fills an unmet need of patients, doctors, and payers around the world since poor compliance leads to escalating health costs due to osteoporosis related fractures" stated Christer Rosén, Chairman and CEO.

About EffRx

EffRx is a privately held drug delivery technology company specializing in the utilization of proprietary effervescent technology to develop formulations that improve efficiency, compliance and convenience of existing prescription drugs.

For additional information please visit the EffRx website http://www.effrx.com  

Contacts:
Christer Rosén
Chairman and CEO
crosen@effrx.com
+41-79-963-66-00

Marshall Hayward
CSO
mhayward@effrx.com
+41-79-963-66-04



'/>"/>
SOURCE EffRx Pharmaceuticals S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
2. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
3. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
4. Rosetta Genomics Announces One-For-Four Reverse Stock Split
5. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
6. Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
7. SCOLR Pharma, Inc. Announces Final Closing of Private Placement
8. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
9. Tengion Announces Leadership Transition
10. The Olive Branch Fund Announces Funding Award to Harvard Researcher
11. Verenium Announces Signing of Lease for New Office and Lab Space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been named ... as WEDI’s interim CEO since January 2016. As an executive leader with more than ...
(Date:5/25/2016)... ... 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) ... company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar Ataxia ... , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is estimated ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ., ... artificial intelligence, real-time decision support tools in the emergency room, ... the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology Week, ... David Intercontinental Hotel in Tel Aviv, Israel ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... a newly re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven ... of imaging and image analysis. The re-branding components include a crisp, refreshed logo ...
Breaking Biology Technology:
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), a company ... of a new series of commercials on Time Warner Cable ... .  The commercials will air on Bloomberg TV, Fox Business ... show. --> NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ...
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
Breaking Biology News(10 mins):